Medication topics
Ozanimod articles covering Zeposia, S1P-modulator therapy, safety, approvals, access, and IBD treatment decisions. Access context emphasizes approvals, coverage, affordability, availability, and policy decisions.
2 articles
New approvals and pipeline activity can expand future treatment options and affect availability, pricing, and research priorities for Crohn’s disease. Market analyses can signal which therapies companies expect to...
The article summarizes a commercial market report that lists current and upcoming Crohn's disease treatments, trial results, and a biosimilar approval — information patients may see reflected in treatment availability,...
